Compared to HER2-positive and HER2-zero expression breast cancer, the prevalence of estrogen receptors (ER) and progesterone receptors (PR) is higher in HER2-low tumors, while Ki67 levels tend to be lower (Marchio et al., 2021; Zhang et al., 2022). This evidence concerns the gene MKI67 and breast cancer.